Global rapid tests Premier Medical Corporation is a biotech manufacturer of rapid diagnostic kits for malaria, HIV, HBsAg, and hCG with a WHO-FIND evaluation noting strong performance. Sales opportunities exist in global health programs, NGOs, and government procurement that require validated RDTs with independent performance data.

Recent malaria expansion The March 2026 launch of First Response Malaria Ag. P.f. /P.f. /P.v. tests expands the malaria portfolio, offering differentiated HRP2 and pLDH targets. This presents cross-sell opportunities to customers who previously purchased malaria RDTs or who require assay differentiation for Plasmodium species in field settings.

Strategic partnerships Past collaborations with iSTOC to deploy mobile and consumer-facing diagnostics indicate a channel strategy that leverages partnerships and direct-to-consumer pilots. Sales teams can explore co-marketing, distributor partnerships, and regional pilots to accelerate market penetration in emerging markets.

Tech-enabled marketing The company employs a mix of web, Office 365, and open-source web tech stack, suggesting potential for digital demand generation, online cataloging, and e-commerce or e-sampling programs to reach regional buyers, clinics, and point-of-care providers efficiently.

Financing and scale With reported revenue between one and ten million and a small employee base, Premier Medical could be a fit for strategic financing or grant-supported procurement programs, enabling larger scale orders, competitive pricing for bulk contracts, and entry into national procurement systems.